Orgenesis Inc. Stock

ORGS

US68619K3032

Medical Equipment, Supplies & Distribution

Delayed OTC Markets 21:31:57 31/08/2026 HKT			5-day change	1st Jan Change
0.3500 ^USD	+218.18%		-40.68%	+133.33%

03-27	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03-26	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâ€™s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâ€™s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
31/08/26	US$0.3500	+218.18%	100
28/08/26	US$0.1100	+236.39%	286
27/08/26	US$0.0327	0.00%	2,767
26/08/26	US$0.0327	-94.36%	1,100
25/08/26	US$0.5800	-1.69%	200

Delayed Quote OTC Markets

More quotes

Market Cap	983K 847K 794K 725K 1.37M 93.93M 1.37M 9.42M 3.68M 47.42M 3.69M 3.61M 157M	P/E 2023	-0.26x	P/E 2024	-0.17x
Enterprise Value	19.16M 16.51M 15.48M 14.13M 26.63M 1.83B 26.71M 184M 71.67M 925M 71.95M 70.38M 3.07B	EV / Sales 2023	71.2x	EV / Sales 2024	27x
Free-Float	52.06%	Yield 2023 *	-	Yield 2024	-

03-27	Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03-26	Orgenesis Inc. Auditor Raises 'Going Concern' Doubt	CI
03-26	Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc..	CI
03-14	Orgenesis Inc. Announces Board Appointments, Effective March 10, 2026	CI
03-14	Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026	CI
26/08/25	Orgenesis Inc. Announces Resignation of Director Ashish Nanda, Effective August 21, 2025	CI
20/08/25	Orgenesis Inc. Announces Resignation of Victor Miller as Chief Financial Officer	CI
20/08/25	Orgenesis Inc. Announces Executive and Board Changes	CI
06/03/25	Orgenesis Inc. completed the acquisition of Certain assets of Neurocords LLC for $5.7 million.	CI
22/01/25	Orgenesis Inc. announced that it expects to receive $5 million in funding	CI
28/12/24	Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director	CI
13/11/24	Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.	CI
13/11/24	Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

03-27	Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)	PU
13/11/24	Orgenesis Provides Third Quarter 2024 Business Update	AQ
21/10/24	Orgenesis Commences Trading on OTCQX® Best Market	AQ
23/09/24	Orgenesis Announces Reverse Stock Split	AQ
29/08/24	Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia	AQ

1 day	+218.18%
1 week	-40.68%
Current month	-50.70%
1 month	-50.70%
3 months	+11,190.32%
6 months	-41.67%
Current year	+133.33%

1 week	0.03	0.79
1 month	0.02	0.79
Current year	0	0.84
1 year	0	1
3 years	0	10.8
5 years	0	54.3
10 years	0	168

Orgenesis Inc. Stock

Stocks

ORGS

US68619K3032

Medical Equipment, Supplies & Distribution

Valuation : Orgenesis Inc.

Chart: Orgenesis Inc.

Latest news : Orgenesis Inc.

Press Releases : Orgenesis Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Orgenesis Inc.

Latest insider transactions

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Sarah Ferber CTO	Chief Tech/Sci/R&D Officer	72	02/02/2012
Vered Caplan CEO	Chief Executive Officer	57	24/12/2013
Douglas Karriker DFI	Director of Finance/CFO	51	10/03/2026

Director	Title	Age	Since
Vered Caplan CHM	Chairman	57	14/08/2014
Itzhak Vider BRD	Director/Board Member	64	08/07/2024
Adam Pelavin BRD	Director/Board Member	47	28/10/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/3/25	Ariel Malik	Other		1,200,000	23.2142%
12/12/24	Itzhak Vider	Free	Director	1,500	0.0290%
12/12/24	Ashish Nanda	Free	Director	1,835	0.0355%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORGENESIS INC.	+218.18%	-40.68%	-56.25%	-93.13%	1.08M
ABBOTT LABORATORIES	-1.84%	-5.11%	-15.78%	+7.59%	195B
MEDTRONIC PLC	-0.23%	-2.09%	-2.54%	+11.61%	117B
CENCORA, INC.	+1.21%	+0.82%	+10.71%	+85.48%	61.45B
BECTON, DICKINSON AND COMPANY	-0.43%	-1.01%	+0.35%	-32.44%	51.62B
HOYA CORPORATION	+0.80%	-1.18%	+27.69%	+52.27%	51.03B
DEXCOM, INC.	-0.77%	-1.15%	+21.14%	-10.86%	34.27B
MEDLINE INC.	-0.78%	+0.72%	-	-	30.95B
WEST PHARMACEUTICAL SERVICES, INC.	+0.92%	-3.11%	+40.45%	-15.87%	23.75B
TERUMO CORPORATION	-0.91%	-3.06%	-6.22%	+14.03%	23.41B
Average	+21.56%	-1.21%	+2.17%	+2.08%	58.79B
Weighted average by Cap.	-0.64%	-1.95%	+0.47%	+15.55%

	2023	2024
Net sales	530K 457K 428K 391K 736K 50.65M 739K 5.08M 1.98M 25.57M 1.99M 1.95M 84.79M	1.03M 892K 836K 763K 1.44M 98.92M 1.44M 9.92M 3.87M 49.93M 3.89M 3.8M 166M
Net income	-55.36M -47.7M -44.73M -40.83M -76.92M -5.29B -77.16M -531M -207M -2.67B -208M -203M -8.86B	-48.16M -41.5M -38.91M -35.52M -66.92M -4.6B -67.13M -462M -180M -2.32B -181M -177M -7.71B
Net Debt	21.78M 18.77M 17.6M 16.07M 30.27M 2.08B 30.36M 209M 81.47M 1.05B 81.79M 80.01M 3.48B	18.18M 15.67M 14.69M 13.41M 25.26M 1.74B 25.34M 174M 68M 877M 68.26M 66.78M 2.91B